The cryptos leave the margins. They settle in the balance sheets. Bitcoin opened the ball, Ethereum followed. Now, some altcoins draw the attention of businesses. Latest to take this step: Litecoin. Biotech Mei Pharma has just struck hard. 100 million dollars injected into a cash strategy exclusively based on this Altcoin. A first in the pharmaceutical sector.
In short
- Mei Pharma becomes the first company Biotech listed to bet exclusively on Litecoin in cash.
- Charlie Lee, creator of Litecoin, joins the board of directors to supervise this unprecedented strategy.
- The Meip action jumped 83 %, while Litecoin earned 12 % in parallel.
- Luxxfolio follows the movement, doubling its LTC reserves and focusing on institutional adoption.
A crypto audacity signed Mei Pharma
Mei Pharma did not just buy Litecoin (LTC). She built around him A new strategic base. This company listed at Nasdaq has risen $ 100 million via a private placement operation (pipe). His goal? Make LTC its main reserve assets. This is the first time that Biopharmaceutical company Dare such a decision.
The event does not stop at purchase. Mei also welcomed Charlie Lee, creator of Litecoin, to his board of directors. He did not chew her words ::
This partnership with GSR and Mei Pharma finally brings the mission of Litecoin in an institutional framework.
With GSR, a leader in Crypto markets, as a digital asset management advisor, Mei hasA formidable pair. Charlie Lee, a recognized pioneer, embodies visionary leadership. GSR, on the other hand, pilots the strategy and supervises the risks. Result : Hybrid governance between biotech, traditional finance and crypto.
LTC in orbit, MEIP in boil
The announcement was not long in causing a stir. Litecoin jumped more than 12 %temporarily reaching $ 108. Its transaction volume has exploded. The Charlie Lee effect? Certainly. But also the institutional effect.
At the same time, The Meip action has climbed 83 % in pre-market, Recording a peak at $ 9.39. The operation of 29 million shares to $ 3.42 each was completed, reflecting a massive enthusiasm of investors.
Luxxfolio Holdingsanother actor side, did not remain of marble. Since March, the company has increased its Litecoin cash from 151.6 % per share, now reaching A total of 20,084 LTC.
This valid a trend : Litecoin is no longer confined to individual payments. He settles in corporate strategies. It becomes a cash flow tool. He becomes active in trust.
Litecoin: the discreet alternative that strikes hard
Why did Mei bet on Litecoin and not on Ethereum or Bitcoin? The answer is double: efficiency and discretion.
Litecoin was designed to be fast, secure and decentralized – and it is exciting to see these principles now adopted by a listed company like Mei.
Charlie Lee, Source: Businesswire.
In parallel, the Litecoin displays massive use in payments. On Bitpay, he sometimes even surpasses Bitcoin in volume of transactions.
And beyond the technical narrative, the figures speak:
- 12.5 % increase in LTC in 24 hours after the announcement;
- 83 % of pre-market gain for Meip;
- 29.2 million shares sold at $ 3.42 to finance the operation;
- 151 % increase in Litecoin cash for Luxxfolio;
- $ 100 million allocated exclusively to the purchase of LTC.
The message is clear: Litecoin is no longer a secondary part. It is an investment tool, a response to volatility, a strategic alternative.
With this unprecedented investment, Mei Pharma opens the way to a new era for altcoins in corporate finance. But Litecoin does not stop there. It now targets the ETFs, as evidenced by the verdict of the dry recently reported on the ETF Litecoin and Solana. While Bitcoin moves to tech giants, LTC explores new markets. One step after another, the gray crypto is making its way to the light.
Maximize your Cointribne experience with our 'Read to Earn' program! For each article you read, earn points and access exclusive rewards. Sign up now and start accumulating advantages.
